📣 VC round data is live. Check it out!

GoodRx Valuation Multiples

Discover revenue and EBITDA valuation multiples for GoodRx and similar public comparables like Talkspace, Moonpig Group, Apotea, EverQuote and more.

GoodRx Overview

About GoodRx

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.


Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

GoodRx Financials

GoodRx reported last 12-month revenue of $787M and EBITDA of $259M.

In the same LTM period, GoodRx generated $725M in gross profit, $259M in EBITDA, and $31M in net income.

Revenue (LTM)


GoodRx P&L

In the most recent fiscal year, GoodRx reported revenue of $797M and EBITDA of $271M.

GoodRx is profitable as of last fiscal year, with gross margin of 93%, EBITDA margin of 34%, and net margin of 4%.

See analyst estimates for GoodRx
LTMLast FY202320242025202620272028
Revenue$787M$797M$750M$792M$797M
Gross Profit$725M$739M$683M$744M$739M
Gross Margin92%93%91%94%93%
EBITDA$259M$271M$109M$154M$184M
EBITDA Margin33%34%15%19%23%
EBIT Margin24%25%(4%)8%11%
Net Profit$31M$30M($9M)$16M$30M
Net Margin4%4%(1%)2%4%
Net Debt—$226M———

Financial data powered by Morningstar, Inc.

GoodRx Stock Performance

GoodRx has current market cap of $867M, and enterprise value of $1B.

Market Cap Evolution


GoodRx's stock price is $2.56.

GoodRx share price increased by 8.5% in the last 30 days, and decreased by 34.7% in the last year.

GoodRx has an EPS (earnings per share) of $0.09.

See more trading valuation data for GoodRx
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$867M0.0%8.5%36.9%-34.7%$0.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

GoodRx Valuation Multiples

GoodRx trades at 1.5x EV/Revenue multiple, and 4.4x EV/EBITDA.

See NTM and 2027E valuation multiples for GoodRx

EV / Revenue (LTM)


GoodRx Financial Valuation Multiples

As of May 8, 2026, GoodRx has market cap of $867M and EV of $1B.

GoodRx has a P/E ratio of 28.3x.

LTMLast FY202320242025202620272028
EV/Revenue1.5x1.4x1.5x1.4x1.4x
EV/EBITDA4.4x4.2x10.5x7.5x6.2x
EV/EBIT6.2x5.8x(42.5x)17.4x13.1x
EV/Gross Profit1.6x1.6x1.7x1.5x1.6x
P/E28.3x28.5x(97.8x)52.9x28.5x
EV/FCF10.1x10.9x13.9x10.1x12.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified GoodRx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

GoodRx Margins & Growth Rates

GoodRx decreased revenue by 4% and EBITDA by 12% in the last fiscal year.

In the most recent fiscal year, GoodRx reported gross margin of 93%, EBITDA margin of 34%, and net margin of 4%.

See estimated margins and future growth rates for GoodRx

GoodRx Margins

Last FY202420252026202720282029
Gross Margin93%94%93%91%
EBITDA Margin34%19%23%31%
EBIT Margin25%8%11%21%
Net Margin4%2%4%4%
FCF Margin13%14%12%17%

GoodRx Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(4%)6%1%(4%)
Gross Profit Growth(5%)9%(1%)(5%)
EBITDA Growth(12%)41%20%28%
EBIT Growth(18%)(344%)33%86%
Net Profit Growth2%(285%)86%2%
FCF Growth22%38%(17%)37%

Data powered by FactSet, Inc. and Morningstar, Inc.

GoodRx Operational KPIs

GoodRx's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.9M for the same period.

GoodRx's Rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

GoodRx's Rule of X is 22% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for GoodRx
LTMLast FY202320242025202620272028
Rule of 4032%27%———
Bessemer Rule of X32%22%———
Revenue per Employee—$1.1M———
Opex per Employee—$0.9M———
S&M Expenses to Revenue39%42%45%46%42%
G&A Expenses to Revenue9%14%17%15%14%
R&D Expenses to Revenue12%15%18%16%15%
Opex to Revenue—82%95%86%82%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Talkspace3.4x3.1x49.4x36.2x
Moonpig Group2.2x2.0x7.8x7.5x
Apotea1.1x1.1x17.4x16.1x
EverQuote1.0x0.9x7.1x6.6x
Pague Menos0.5x0.5x6.1x7.2x
Dmall2.7x2.1x(2.1x)35.0x
Luyan Pharma0.5x—14.6x—
Shu Yu Civilian Pharmacy0.7x—10.2x—

This data is available for Pro users. Sign up to see all GoodRx competitors and their valuation data.

Start Free Trial

GoodRx Funding History

Before going public, GoodRx raised $909M in total equity funding, across 3 rounds.

Last private valuation of GoodRx was $3B, after raising $100M in September 2020 from Silver Lake and TCV.


GoodRx Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Sep-20Undisclosed stageSilver Lake; TCV$100M$3BGoodRx is a price comparison platform that helps consumers find discounted prescription drug prices at local pharmacies through digital coupons and pricing transparency tools. The company was founded by Douglas Hirsch and Trevor Bezdek and is headquartered in Santa Monica, California. For the first half of 2020, GoodRx reported $257 million in revenue and nearly $55 million in net income, demonstrating profitability ahead of its public market debut. Growth investor Silver Lake made an additional $100 million investment in GoodRx via private placement concurrent with the company's IPO in September 2020, after having initially invested in the company in 2018 at a $2.8 billion valuation. Silver Lake's follow-on investment brought their total ownership stake to approximately 35.3% prior to the IPO. In September 2020, GoodRx priced its IPO at $33 per share, above the initially targeted $24-$28 range, raising approximately $1.14 billion and achieving an initial public market valuation of $12.7 billion. The company was backed by other major investors including Francisco Partners (23.7% pre-IPO stake) and Spectrum Equity (15.4%), and the IPO positioned GoodRx as a rare profitable technology company entering public markets during that period.
May-20Undisclosed stageFrancisco Partners; Silver Lake; Spectrum Equity$60M—GoodRx is a digital healthcare platform providing prescription savings, telehealth, and price transparency services in the United States. The company connects consumers with pharmacies for discounted drug prices and offers additional services like GoodRx Gold membership and telehealth consultations. GoodRx's financial performance in 2020 showed strong growth, with annual revenue reaching $550.70 million for the fiscal year ended December 31, 2020, up 41.85% from $388.22 million in 2019. The revenue growth reflected expanding adoption of its prescription discount platform amid rising healthcare costs and consumer demand for affordability. GoodRx went public in September 2020 via direct listing on Nasdaq under GDRX, after which investor involvement shifted from traditional VC structures. Subsequent years saw revenue continue to grow, reaching $745.42 million in 2021 and $792.32 million in 2024.
Aug-18Undisclosed stageFrancisco Partners; Silver Lake; Spectrum Equity$749M$3BGoodRx, a digital healthcare platform providing prescription price comparison and savings, received a major investment from Silver Lake Management in August 2018, valuing the company at $2.8 billion. This aligns closely with the queried June 2018 round involving Francisco Partners, Silver Lake, and Spectrum Equity, with Silver Lake as lead. The investment supported GoodRx's growth in its prescription transaction platform, which generated the majority of revenue through fees from pharmacy benefit managers. In 2018, GoodRx reported $250 million in revenue, up significantly from prior years, reflecting strong growth with a compound annual growth rate of 57% since 2016. The company had approximately 718,000 monthly active users by March 2016, expanding to millions by later periods. GoodRx continued rapid expansion, reaching $388 million revenue in 2019 and achieving profitability, with cumulative consumer savings exceeding $20 billion by mid-2020.

GoodRx M&A Activity

GoodRx has acquired 6 companies to date.

Last acquisition by GoodRx was on March 7th 2022. GoodRx acquired VitaCare for $150M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by GoodRx

VitaCare
RxSaver
HealthiNation
Scriptcycle
Description
VitaCare is a Boca Raton-headquartered technology platform that supports patient access and adherence to brand-name medications. Established in 2014, it offers services to overcome reimbursement hurdles, prescription fulfillment, and ongoing therapy management for pharmaceutical brands. The company partners with drug manufacturers to provide copay assistance, prior authorization support, and digital tools that improve treatment persistence in the United States.
RxSaver is a free prescription discount program accessible nationwide through its website, mobile app, and savings card. It negotiates discounted prices at over 68,000 pharmacies, covering brand-name and generic medications without eligibility requirements or enrollment fees.
HealthiNation is a New York-headquartered producer of health education videos distributed on YouTube, apps, and TV reaching 100 million annual views. Content spans diabetes management, smoking cessation, exercise routines, and multiple sclerosis care through channels like HealthiNation and Everyday Health. Acquired by Ziff Davis in 2016, it partners with pharma like Pfizer for sponsored series.
Scriptcycle is a prescription program manager partnering with pharmacies and PBMs to deliver cost-effective drug access. It designs transparent plans reducing out-of-pocket costs for patients in underserved communities. Scriptcycle operates nationwide, focusing on chronic disease medications and specialty pharmacy services.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Boca Raton, FL
Austin, TX
New York City, NY
Asheville, NC
Deal Date7 Mar 202213 May 202119 Apr 202131 Aug 2020
Valuation$150M$50M$75M$63M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all GoodRx acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About GoodRx

When was GoodRx founded?GoodRx was founded in 2015.
Where is GoodRx headquartered?GoodRx is headquartered in United States.
How many employees does GoodRx have?As of today, GoodRx has over 738 employees.
Who is the CEO of GoodRx?GoodRx's CEO is Wendy Barnes.
Is GoodRx publicly listed?Yes, GoodRx is a public company listed on Nasdaq.
What is the stock symbol of GoodRx?GoodRx trades under GDRX ticker.
When did GoodRx go public?GoodRx went public in 2020.
Who are competitors of GoodRx?GoodRx main competitors include Talkspace, Moonpig Group, Apotea, EverQuote, Pague Menos, Dmall, Luyan Pharma, Shu Yu Civilian Pharmacy, QuinStreet, Bukalapak.com.
What is the current market cap of GoodRx?GoodRx's current market cap is $867M.
What is the current revenue of GoodRx?GoodRx's last 12 months revenue is $787M.
What is the current revenue growth of GoodRx?GoodRx revenue growth (NTM/LTM) is (0%).
What is the current EV/Revenue multiple of GoodRx?Current revenue multiple of GoodRx is 1.5x.
Is GoodRx profitable?Yes, GoodRx is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of GoodRx?GoodRx's last 12 months EBITDA is $259M.
What is GoodRx's EBITDA margin?GoodRx's last 12 months EBITDA margin is 33%.
What is the current EV/EBITDA multiple of GoodRx?Current EBITDA multiple of GoodRx is 4.4x.
What is the current FCF of GoodRx?GoodRx's last 12 months FCF is $114M.
What is GoodRx's FCF margin?GoodRx's last 12 months FCF margin is 14%.
What is the current EV/FCF multiple of GoodRx?Current FCF multiple of GoodRx is 10.1x.
How many companies GoodRx has acquired to date?As of May 2026, GoodRx has acquired 6 companies.
What was the largest acquisition by GoodRx?$150M acquisition of VitaCare on 7th March 2022 was the largest M&A GoodRx has done to date.
What companies GoodRx acquired?GoodRx acquired VitaCare, HealthiNation, Scriptcycle, RxSaver, HeyDoctor, and Iodine.
In how many companies GoodRx has invested to date?GoodRx hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to GoodRx

Lists including GoodRx

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial